bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Variables Affecting CA15.3 Tumor Antigen Expression and Antibodies against It in Female National Health and Nutritional Survey Participants
Authors: Cramer Daniel W. , Vitonis Allison F. , Fichorova Raina N. , Yamamoto Hidemi S. , Mudugno Francesmary , Finn Olivera J.
Published: September 2024

AbstractBackground:
Cancers of ductal origin often express glycoprotein mucin 1 (MUC1), also known as CA15.3, with higher levels leading to poor prognosis. Conversely, anti-MUC1 antibodies develop in some patients, leading to better prognosis. We sought to identify epidemiologic factors associated with CA15.3 antigen or antibody levels.
Methods:
Levels of CA15.3 antigen and anti-CA15.3 IgG antibodies were measured in archived sera from 2,302 mostly healthy women from the National Health and Nutritional Survey; and epidemiologic predictors of their levels were examined using multivariate and correlational analyses.
Results:
Among racial groups, Black women had the highest levels of CA15.3 antigen and lowest levels of antibodies. Increasing body mass index and current smoking were associated with low anti-CA15.3 antibody levels. Low CA15.3 antigen levels were seen in oral contraceptive users and high levels in women who were pregnant or lactating at the time of blood collection, with the latter group also having high antibody levels. Past reproductive events associated with high antigen levels included the following: later age at menarche, having given birth, and history of endometriosis. Lower antigen levels were seen with increasing duration of OC use. Anti-CA15.3 antibody levels decreased with an increasing estimated number of ovulatory years.
Conclusions:
Key determinants of CA.15.3 antigen or antibody levels include the following: race, body mass index, smoking, later menarche, childbirth, number of ovulatory cycles, and endometriosis.
Impact:
This study supports the premise that known epidemiologic factors affecting risk for or survival after MUC1-expressing cancers may, at least partially, operate through their association with CA15.3 antigen or antibody levels.
Supplementary Table S7 from Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning
Authors: Reinecke David , Ruess Daniel , Meissner Anna-Katharina , Fürtjes Gina , von Spreckelsen Niklas , Ion-Margineanu Adrian , Khalid Florian , Blau Tobias , Stehle Thomas , Al-Shugri Abdulkader , Büttner Reinhard , Goldbrunner Roland , Ruge Maximilian I. , Neuschmelting Volker
Published: September 2024

Supplementary Table S7. Illustration of each deep-learning model’s best prediction performance on SRH images with ≥130 high-quality patches (first model) and >140 high-quality patches (second and third model) after stepwise metric performance evaluation. The second model was used to predict the class of each acquired entity from small biopsy tissue samples. The level of accuracy depended on the final integrated diagnosis and the predefined model label assignment to the respective subclasses.
Supplementary Table S6 from Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning
Authors: Reinecke David , Ruess Daniel , Meissner Anna-Katharina , Fürtjes Gina , von Spreckelsen Niklas , Ion-Margineanu Adrian , Khalid Florian , Blau Tobias , Stehle Thomas , Al-Shugri Abdulkader , Büttner Reinhard , Goldbrunner Roland , Ruge Maximilian I. , Neuschmelting Volker
Published: September 2024

Supplementary Table S6. The second model was used to predict the class of each acquired entity from small biopsy tissue samples. These predictions were compared to the frozen section diagnosis after tumor radiotherapy. The level of accuracy depended on the final diagnosis and the predefined model label assignment to the respective subclasses.
Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Authors: Lee Horace H.Y. , Chow Kin Long , Wong Ho Shing , Chong Tsz Yan , Wong Alice S.T. , Cheng Grace H.W. , Ko Jasmine M.K. , Siu Hoi Cheong , Yeung Maximus C.F. , Huen Michael S.Y. , Tse Ka Yu , Bray Mark R. , Mak Tak Wah , Leung Suet Yi , Ip Philip P.C.
Published: September 2024

Supplementary Figure S4. Autopsy findings on two mice from two different 5 mg/kg CFI-400945 treatment groups that were withdrawn from the experiments (hematoxylin and eosin staining).
Table S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Table S4. Adverse events.
Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Table S3. Representativeness of study participants.
Supplementary Figure S3 from Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Garrabou Glòria , Cardús Oriol , Díaz Tania , Moreno David F. , Mañé-Pujol Joan , Oliver-Caldés Aina , Battram Anthony , Tovar Natalia , Cibeira María-Teresa , Rodríguez-Lobato Luis-Gerardo , Bladé Joan , Fernández de Larrea Carlos , Rosiñol Laura
Published: September 2024

Supplementary Figure S3: Transcriptomic analysis CD8 T cells on PVR or nectin2
Supplementary Figure S1 from Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Garrabou Glòria , Cardús Oriol , Díaz Tania , Moreno David F. , Mañé-Pujol Joan , Oliver-Caldés Aina , Battram Anthony , Tovar Natalia , Cibeira María-Teresa , Rodríguez-Lobato Luis-Gerardo , Bladé Joan , Fernández de Larrea Carlos , Rosiñol Laura
Published: September 2024

Supplementary Figure S1: Gating strategy
Supplemental Table 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Authors: Lenis Andrew T. , Ravichandran Vignesh , Brown Samantha , Alam Syed M. , Katims Andrew , Truong Hong , Reisz Peter A. , Vasselman Samantha , Nweji Barbara , Autio Karen A. , Morris Michael J. , Slovin Susan F. , Rathkopf Dana , Danila Daniel , Woo Sungmin , Vargas Hebert A. , Laudone Vincent P. , Ehdaie Behfar , Reuter Victor , Arcila Maria , Berger Michael F. , Viale Agnes , Scher Howard I. , Schultz Nikolaus , Gopalan Anuradha , Donoghue Mark T.A. , Ostrovnaya Irina , Stopsack Konrad H. , Solit David B. , Abida Wassim
Published: September 2024

Supplemental Table 1
Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: French Jena D. , Haugen Bryan R. , Worden Francis P. , Bowles Daniel W. , Gianoukakis Andrew G. , Konda Bhavana , Dadu Ramona , Sherman Eric J. , McCue Shaylene , Foster Nathan R. , Nikiforov Yuri E. , Farias Ticiana D.J. , Norman Paul J. , Wirth Lori J.
Published: September 2024

Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Biomarker Analyses in Cohort 2 Supplementary Table 5. Peripheral Blood Biomarker Analyses in Cohort 1 Supplementary Table 6. Peripheral Blood Biomarker Analyses in Cohort 2 Supplementary Table 7. Mutations in Cohort 1 Supplementary Table 8. Mutations in Cohort 2
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Authors: Lenis Andrew T. , Ravichandran Vignesh , Brown Samantha , Alam Syed M. , Katims Andrew , Truong Hong , Reisz Peter A. , Vasselman Samantha , Nweji Barbara , Autio Karen A. , Morris Michael J. , Slovin Susan F. , Rathkopf Dana , Danila Daniel , Woo Sungmin , Vargas Hebert A. , Laudone Vincent P. , Ehdaie Behfar , Reuter Victor , Arcila Maria , Berger Michael F. , Viale Agnes , Scher Howard I. , Schultz Nikolaus , Gopalan Anuradha , Donoghue Mark T.A. , Ostrovnaya Irina , Stopsack Konrad H. , Solit David B. , Abida Wassim
Published: September 2024

Supplemental Figure 3
Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: French Jena D. , Haugen Bryan R. , Worden Francis P. , Bowles Daniel W. , Gianoukakis Andrew G. , Konda Bhavana , Dadu Ramona , Sherman Eric J. , McCue Shaylene , Foster Nathan R. , Nikiforov Yuri E. , Farias Ticiana D.J. , Norman Paul J. , Wirth Lori J.
Published: September 2024

Tumor density of CD8 T cells and myeloid subsets in DTC tumors
Supplementary Table S3 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Clinical data for patient plasma samples.
Supplementary Table S2 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Tumor TP53 and RB1 status for tSCLC tumors in the PDX and cfDNA cohorts.
Supplementary Table S1 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Clinical data for PDX models.
Supplementary Figure S8 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Representative epigenomic data from an EGFRm tSCLC and EGFRm LUAD showing the distribution of H3K27ac and H3K4me3 signal intensity near INSM1, a neural lineage-defining gene.
Supplementary Figure S6 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Volcano plot showing overlap of differentially expressed genes between LUAD and SCLC PDXs with respective differential H3K4me3 ChIP-seq and ATAC-seq peaks enriched in LUAD and SCLC PDXs.
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
Authors: Pakola Santeri A. , Peltola Katriina J. , Clubb James H.A. , Jirovec Elise , Haybout Lyna , Kudling Tatiana V. , Alanko Tuomo , Korpisaari Riitta , Juteau Susanna , Jaakkola Marjut , Sormunen Jorma , Kemppainen Jukka , Hemmes Annabrita , Pellinen Teijo , van der Heijden Mirte , Quixabeira Dafne C.A. , Kistler Claudia , Sorsa Suvi , Havunen Riikka , Santos Joao M. , Cervera-Carrascon Victor , Hemminki Akseli
Published: September 2024

Supplementary Table S1-S5, Supplementary Figure S1-S6
Supplementary Table S7 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S7. Summary of HRS cell states for each patient.
Supplemental Table 2 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Table 2. 5’ fusion gene partners.
Supplementary Figure S3 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Figure S3. FOV placement for mpIF.
Supplementary Figure S10 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Figure S10. Quantification of HRS cell patterns of spatial organization.
Supplementary Data 1 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Authors: Cui Jian , Li Xiaoyun , Deng Shuhui , Du Chenxing , Fan Huishou , Yan Wenqiang , Xu Jingyu , Li Xiaoqing , Yu Tengteng , Zhang Shuaishuai , Lv Rui , Sui Weiwei , Hao Mu , Du Xin , Xu Yan , Yi Shuhua , Zou Dehui , Cheng Tao , Qiu Lugui , Gao Xin , An Gang
Published: September 2024

Supplementary figure 1-9
Supplementary Figure S5 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

Supplementary Figure S5
Supplementary Figure S3 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

Supplementary Figure S3
GO42144 INVESTIGATORS AND STUDY GROUP1 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

GO42144 INVESTIGATORS AND STUDY GROUP
Supplementary Figure S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Authors: Jank Paul , Karn Thomas , van Mackelenbergh Marion , Lindner Judith , Treue Denise , Huober Jens , Engels Knut , Solbach Christine , Diebold Kurt , Marmé Frederik , Müller Volkmar , Schneeweiss Andreas , Sinn Hans-Peter , Fehm Tanja , Schem Christian , Stickeler Elmar , Fasching Peter , Budczies Jan , Felder Bärbel , Nekljudova Valentina , Holtschmidt Johannes , Untch Michael , Denkert Carsten , Loibl Sibylle
Published: September 2024

Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
Supplementary Table S1 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Table S1. NSCLC Tier 1 SNPs identified in patient primary tumors and matched PDTOs.
Supplementary Methods S1 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Methods S1. Detailed supplementary methods.
Supplementary File S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary File S4. Differentially expressed genes between resistant versus sensitive patient tumors (categorized based on PDTOs therapy outcome).
Supplementary File S2 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary File S2. Somatic small insertion and deletions (INDELs) identified in PDTOs and matched patient tumors.
Supplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
Supplementary Figure S11 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S11. Dose titration of carboplatin and paclitaxel against resistant PDTOs MU375 and MU383 in presence of 1 µM Epalrestat.
Data from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Authors: van Berge Henegouwen Jade M. , Zeverijn Laurien J. , Geurts Birgit S. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , Huitema Alwin D.R. , de Vos Filip Y.F. , Grünberg Katrien , Bloemendal Haiko J. , Verheul Henk M.W. , Voest Emile E. , Gelderblom Hans
Published: September 2024

AbstractPurpose:
Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening eligibility criteria, especially for patients with advanced or treatment-refractory disease. Yet, the impact on patient safety remains uncertain. In the Drug Rediscovery Protocol (DRUP), protocol exceptions are frequently requested and occasionally granted. Here we describe the impact of these waivers on treatment safety and efficacy.
Experimental Design:
DRUP is a multicenter, nonrandomized clinical basket trial treating patients with therapy-refractory cancer with molecularly targeted and immunotherapies outside their registered indications (NCT02925234). Here, all granted waivers were revised, analyzed in terms of safety and efficacy outcome, and comparedwithoutcomes of includedpatientswho didnot receive awaiver.
Results:
Between September 1, 2016, and September 1, 2021, protocol waivers were granted for 82 patients (8%) of 1,019 included patients in DRUP. Most waivers (45%) were granted for general- or drug-related eligibility criteria; other categories were out-of-window testing, treatment, and testing exceptions. Serious adverse event rate was similar between patients who received a waiver (pW) and patients who did not (pNW): 39% vs. 41%, respectively (P = 0.81). The clinical benefit (either objective response or stable disease ≥ 16 weeks) rate of pW was 40% versus 33% in pNW (P = 0.43).
Conclusions:
Safety and clinical benefit were preserved in patients for whom a waiver was granted. These data support a more personalized approach in assessing eligibility criteria, especially in trials with widely used and approved drugs accruing patients without other treatment options.

See related commentary by Waqar and Govindan, p. 3655
Data from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Authors: Lenis Andrew T. , Ravichandran Vignesh , Brown Samantha , Alam Syed M. , Katims Andrew , Truong Hong , Reisz Peter A. , Vasselman Samantha , Nweji Barbara , Autio Karen A. , Morris Michael J. , Slovin Susan F. , Rathkopf Dana , Danila Daniel , Woo Sungmin , Vargas Hebert A. , Laudone Vincent P. , Ehdaie Behfar , Reuter Victor , Arcila Maria , Berger Michael F. , Viale Agnes , Scher Howard I. , Schultz Nikolaus , Gopalan Anuradha , Donoghue Mark T.A. , Ostrovnaya Irina , Stopsack Konrad H. , Solit David B. , Abida Wassim
Published: September 2024

AbstractPurpose:
Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune checkpoint blockade (ICB) in patients with MSI-H/dMMR and TMB-H prostate cancers without MSI [TMB-H/microsatellite stable (MSS)].
Experimental Design:
We sequenced 3,244 tumors from 2,257 patients with prostate cancer. MSI-H/dMMR prostate cancer was defined as an MSIsensor score ≥10 or MSIsensor score ≥3 and <10 with a deleterious MMR alteration. TMB-H was defined as ≥10 mutations/megabase. PSA50 and RECIST responses were assigned. Overall survival and radiographic progression-free survival (rPFS) were compared using log-rank test.
Results:
Sixty-three (2.8%) men had MSI-H/dMMR, and 33 (1.5%) had TMB-H/MSS prostate cancers. Patients with MSI-H/dMMR and TMB-H/MSS tumors more commonly presented with grade group 5 and metastatic disease at diagnosis. MSI-H/dMMR tumors had higher TMB, indel, and neoantigen burden compared with TMB-H/MSS. Twenty-seven patients with MSI-H/dMMR and 8 patients with TMB-H/MSS tumors received ICB, none of whom harbored polymerase epsilon (polE) catalytic subunit mutations. About 45% of patients with MSI-H/dMMR had a RECIST response, and 65% had a PSA50 response. No patient with TMB-H/MSS had a RECIST response, and 50% had a PSA50 response. rPFS tended to be longer in patients with MSI-H/dMMR than in patients with TMB-H/MSS who received immunotherapy. Pronounced differences in genomics, TMB, or MSIsensor score were not detected between MSI-H/dMMR responders and nonresponders.
Conclusions:
MSI-H/dMMR prostate cancers have greater TMB, indel, and neoantigen burden than TMB-H/MSS prostate cancers, and these differences may contribute to profound and durable responses to ICB.
Data from A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Chen Dongjian , Zhu Yu , Chen Zhi , Jiang Songfu , He Haiyan , Qiang Wanting , Xiang Fang , Sun Xuedong , Du Juan
Published: September 2024

AbstractPurpose:
This study aimed to report the 5-year clinical outcomes of anti–B-cell maturation antigen chimeric antigen receptor (CAR) T-cell (HDS269B) therapy in patients with relapsed/refractory multiple myeloma (RRMM), including those with poor performance status [Eastern Cooperative Oncology Group (ECOG) scores 3 to 4], and to identify factors influencing long-term outcomes.
Patients and Methods:
Forty-nine patients with RRMM enrolled from 2016 to 2020 received HDS269B (9 × 106 cells/kg) after receiving a conditioning chemotherapy consisting of cyclophosphamide and fludarabine. The overall response, long-term outcomes, and safety were assessed, as were their associations with clinical and disease characteristics.
Results:
With a median follow-up of 59.0 months, the overall response rate was 77.55%. The median progression-free survival (PFS) and overall survival (OS) were 9.5 months [95% confidence interval (CI), 5.01–13.99] and 20.0 months (95% CI, 11.26–28.74), respectively. The 5-year PFS and OS rates were 21.3% (95% CI, 12.3%–36.7%) and 34.1% (95% CI, 22.7%–51.3%), respectively. Patients with ECOG 0 to 2 had marked longer survival, with a median PFS of 11.0 months and a median OS of 41.8 months. Early minimal residual disease negativity, higher and persistent CAR T-cell expansion, and the absence of extramedullary disease were associated with better survival outcomes. No new CAR T-cell therapy–associated toxicities were observed. Importantly, ECOG scores 0 to 2, prior therapy lines <4, and CAR T-cell persistence at ≥6 months were independently associated with longer OS.
Conclusions:
HDS269B is effective and safe, especially for patients with ECOG scores 0 to 2. Early CAR T-cell intervention may improve prognosis in patients with RRMM.
Data from Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Forster Martin , Brana Irene , Pousa Antonio L. , Doger Bernard , Roxburgh Patricia , Bajaj Pawan , Peguero Julio , Krebs Matthew , Carcereny Enric , Patel Grisma , Mueller Christian , Brignone Chrystelle , Triebel Frederic
Published: September 2024

AbstractPurpose:
Eftilagimod alpha (efti), a soluble LAG3 protein, activates antigen-presenting cells (APC) and downstream T cells. TACTI-002 (part C) evaluated whether combining efti with pembrolizumab led to strong antitumor responses in patients with second-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) while demonstrating good tolerability.
Patients and Methods:
In this multinational phase II trial using Simon’s two-stage design, patients who were PD-L(1)-naïve with R/M HNSCC who had failed first-line platinum-based therapy, unselected for PD-L1, received intravenous pembrolizumab (200 mg, once every 2 weeks) combined with subcutaneous efti (30 mg once every 2 weeks for 24 weeks and once every 3 weeks thereafter). The primary endpoint was objective response rate per RECIST 1.1 modified for immune-based therapy by investigator assessment. Additional endpoints included duration of response, progression-free survival, overall survival, and tolerability. Pharmacodynamic effects (absolute lymphocyte count) and Th1 cytokine biomarkers (IFNγ/CXCL10)] were evaluated in liquid biopsies.
Results:
Between March 2019 and January 2021, 39 patients were enrolled; 37 were evaluated for response. All patients received prior chemotherapy, and 40.5% were pretreated with cetuximab; 53.1% of patients had PD-L1 combined positive score <20. With a median follow-up of 38.8 months, the objective response rate was 29.7%, including 13.5% complete responders. The median duration of response was not reached. Rapid and sustained absolute lymphocyte count increase was observed in patients who had an objective response. Th1 biomarkers increased sustainably after first treatment. No unexpected safety signals were observed.
Conclusions:
Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in patients with second-line head and neck squamous cell carcinoma (HNSCC), thus supporting further evaluation of this combination in earlier treatment lines.
Supplementary Table S4 from Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles
Authors: Liu Chengdong , Zhou Xiaohan , Zeng Hanyi , Yu Jiaping , Li Wenwen , Zhang Wanli , Liao Yanxia , Wang Haijian , Liu Li
Published: September 2024

Supplementary Table S4
Supplementary Table S2 from Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles
Authors: Liu Chengdong , Zhou Xiaohan , Zeng Hanyi , Yu Jiaping , Li Wenwen , Zhang Wanli , Liao Yanxia , Wang Haijian , Liu Li
Published: September 2024

Supplementary Table S2
Table S5 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Presentation of patients included in CA209-9UP.
Table S4 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Supplementary Table 4
Table S1 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Inclusion and exclusion criteria of the protocol
Figure S2 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Flow cytometry analysis.
Figure S14 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

HLA expression on live cells in tumor digest
Figure S1 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Clinical trial setup.
Supplementary Table 3 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Authors: Sulsenti Roberta , Scialpi Giuseppina B. , Frossi Barbara , Botti Laura , Ferri Renata , Tripodi Irene , Piva Annamaria , Sangaletti Sabina , Pernici Davide , Cancila Valeria , Romeo Francesco , Chiodoni Claudia , Lecis Daniele , Bianchi Francesca , Fischetti Irene , Enriquez Claudia , Crivelli Filippo , Bregni Marco , Renne Giuseppe , Pece Salvatore , Tripodo Claudio , Pucillo Carlo E. , Colombo Mario P. , Jachetti Elena
Published: September 2024

Supplementary table 3 - List of putative NEPC-specific surface TLR ligands
Supplementary Figure S3 from PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Authors: Franzolin Giulia , Brundu Serena , Cojocaru Carina F. , Curatolo Aurora , Ponzo Matteo , Mastrantonio Roberta , Mihara Emiko , Kumanogoh Atsushi , Suga Hiroaki , Takagi Junichi , Tamagnone Luca , Giraudo Enrico
Published: September 2024

PLXNB1 depletion induces higher number of infiltrating macrophages in 4T1 tumors and induces a shift toward M1 gene polarization in ex-vivo models.
Supplementary Figure S1 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Authors: Sulsenti Roberta , Scialpi Giuseppina B. , Frossi Barbara , Botti Laura , Ferri Renata , Tripodi Irene , Piva Annamaria , Sangaletti Sabina , Pernici Davide , Cancila Valeria , Romeo Francesco , Chiodoni Claudia , Lecis Daniele , Bianchi Francesca , Fischetti Irene , Enriquez Claudia , Crivelli Filippo , Bregni Marco , Renne Giuseppe , Pece Salvatore , Tripodo Claudio , Pucillo Carlo E. , Colombo Mario P. , Jachetti Elena
Published: September 2024

Supplementary Figure S1. Flow cytometry evaluation of murine MC purity and maturation in vitro. A. Gating strategy used to evaluate the purity and maturation of WT, OPN-/-, MyD88-/- and TNFa-/-MCs by flow cytometry. Mature MC population is identified as c-Kit+FceRI+.
Figure S5 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Authors: Oberstein Paul E. , Dias Costa Andressa , Kawaler Emily A. , Cardot-Ruffino Victoire , Rahma Osama E. , Beri Nina , Singh Harshabad , Abrams Thomas A. , Biller Leah H. , Cleary James M. , Enzinger Peter , Huffman Brandon M. , McCleary Nadine J. , Perez Kimberly J. , Rubinson Douglas A. , Schlechter Benjamin L. , Surana Rishi , Yurgelun Matthew B. , Wang S. Jennifer , Remland Joshua , Brais Lauren K. , Bollenrucher Naima , Chang Eugena , Ali Lestat R. , Lenehan Patrick J. , Dolgalev Igor , Werba Gregor , Lima Cibelle , Keheler C. Elizabeth , Sullivan Keri M. , Dougan Michael , Hajdu Cristina , Dajee Maya , Pelletier Marc R. , Nazeer Saloney , Squires Matthew , Bar-Sagi Dafna , Wolpin Brian M. , Nowak Jonathan A. , Simeone Diane M. , Dougan Stephanie K.
Published: September 2024

Supplemental Figure 5: Addition of TNFa ameliorates myeloid suppression in vitro. (A) Histogram of HLA-DR mean fluorescence intensity of CD33+ SSCA high cells from monocytes cocultured for a week with 75 pg/ML M-CSF with the addition of 10 ng/mL each GM-CSF/ IL-6 or 10ng/mL IL-1b with or without an IL-1b blocking antibody. (B) Induced MoMDSCs from panel A were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Proliferation indices were calculated. (C) MoMDSCs induced from monocytes cultured for 7 days with the indicated cytokines were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Representative histograms are shown. (D) Proliferation indices from the data shown in C were calculated.
Figure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Authors: Oberstein Paul E. , Dias Costa Andressa , Kawaler Emily A. , Cardot-Ruffino Victoire , Rahma Osama E. , Beri Nina , Singh Harshabad , Abrams Thomas A. , Biller Leah H. , Cleary James M. , Enzinger Peter , Huffman Brandon M. , McCleary Nadine J. , Perez Kimberly J. , Rubinson Douglas A. , Schlechter Benjamin L. , Surana Rishi , Yurgelun Matthew B. , Wang S. Jennifer , Remland Joshua , Brais Lauren K. , Bollenrucher Naima , Chang Eugena , Ali Lestat R. , Lenehan Patrick J. , Dolgalev Igor , Werba Gregor , Lima Cibelle , Keheler C. Elizabeth , Sullivan Keri M. , Dougan Michael , Hajdu Cristina , Dajee Maya , Pelletier Marc R. , Nazeer Saloney , Squires Matthew , Bar-Sagi Dafna , Wolpin Brian M. , Nowak Jonathan A. , Simeone Diane M. , Dougan Stephanie K.
Published: September 2024

Supplemental Figure 1: Progression-free survival for SR-1, an open-label multicenter phase Ib study evaluating gemcitabine, n(ab)-paclitaxel, canakinumab and spartalizumab in advanced pancreatic ductal adenocarcinoma. A) PFS for the 10 patients in SR-1 is shown. B) OS for the 10 patients in SR-1 is shown. C) PFS for the 11 patients in the GnP cohort is shown.
Table S5 from Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Authors: De Munter Stijn , Buhl Juliane L. , De Cock Laurenz , Van Parys Alexander , Daneels Willem , Pascal Eva , Deseins Lucas , Ingels Joline , Goetgeluk Glenn , Jansen Hanne , Billiet Lore , Pille Melissa , Van Duyse Julie , Bonte Sarah , Vandamme Niels , Van Dorpe Jo , Offner Fritz , Leclercq Georges , Taghon Tom , Depla Erik , Tavernier Jan , Kerre Tessa , Drost Jarno , Vandekerckhove Bart
Published: September 2024

Differentially expressed genes in nanoCAR T-cells from cluster CD8WT vs CD4WT
Figure S5 from MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming
Authors: Zewdie Eden Y. , Edwards George M. , Hunter Debra M. , Earp Henry Shelton , Holtzhausen Alisha
Published: September 2024

Supplemental Figure 5
Supplementary Figure 8 from Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis
Authors: Castro-Pando Susana , Howell Rian M. , Li Le , Mascaro Marilina , Faraoni Erika Y. , Le Roux Olivereen , Romanin David , Tahan Virginia , Riquelme Erick , Zhang Yu , Kolls Jay K. , Allison James P. , Lozano Guillermina , Moghaddam Seyed J. , McAllister Florencia
Published: September 2024

Supplementary Figure 8: IL/IL17-A signaling inhibits CD8 activation
Supplementary Figure 8 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Authors: Porte Sarah , Audemard-Verger Alexandra , Wu Christian , Durand Aurélie , Level Théo , Giraud Léa , Lombès Amélie , Germain Mathieu , Pierre Rémi , Saintpierre Benjamin , Lambert Mireille , Auffray Cédric , Peyssonnaux Carole , Goldwasser François , Vaulont Sophie , Alves-Guerra Marie-Clotilde , Dentin Renaud , Lucas Bruno , Martin Bruno
Published: September 2024

Impact of iron on the expression of PD1 or PD-L1 on T cells or tumor cells respectively.
Supplementary Figure 1 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Authors: Porte Sarah , Audemard-Verger Alexandra , Wu Christian , Durand Aurélie , Level Théo , Giraud Léa , Lombès Amélie , Germain Mathieu , Pierre Rémi , Saintpierre Benjamin , Lambert Mireille , Auffray Cédric , Peyssonnaux Carole , Goldwasser François , Vaulont Sophie , Alves-Guerra Marie-Clotilde , Dentin Renaud , Lucas Bruno , Martin Bruno
Published: September 2024

Gating strategy defining T-cell subsets.
Table S3 from Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Authors: De Munter Stijn , Buhl Juliane L. , De Cock Laurenz , Van Parys Alexander , Daneels Willem , Pascal Eva , Deseins Lucas , Ingels Joline , Goetgeluk Glenn , Jansen Hanne , Billiet Lore , Pille Melissa , Van Duyse Julie , Bonte Sarah , Vandamme Niels , Van Dorpe Jo , Offner Fritz , Leclercq Georges , Taghon Tom , Depla Erik , Tavernier Jan , Kerre Tessa , Drost Jarno , Vandekerckhove Bart
Published: September 2024

Differentially expressed genes in nanoCAR T-cells from cluster CD4KO vs CD4WT
Supplemental Figure S8 from Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Authors: De Munter Stijn , Buhl Juliane L. , De Cock Laurenz , Van Parys Alexander , Daneels Willem , Pascal Eva , Deseins Lucas , Ingels Joline , Goetgeluk Glenn , Jansen Hanne , Billiet Lore , Pille Melissa , Van Duyse Julie , Bonte Sarah , Vandamme Niels , Van Dorpe Jo , Offner Fritz , Leclercq Georges , Taghon Tom , Depla Erik , Tavernier Jan , Kerre Tessa , Drost Jarno , Vandekerckhove Bart
Published: September 2024

CD70 WT and KO CD70-specific nanoCAR T-cells have a distinct transcriptional profile after production.
Data from PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Authors: Franzolin Giulia , Brundu Serena , Cojocaru Carina F. , Curatolo Aurora , Ponzo Matteo , Mastrantonio Roberta , Mihara Emiko , Kumanogoh Atsushi , Suga Hiroaki , Takagi Junichi , Tamagnone Luca , Giraudo Enrico
Published: September 2024

Abstract
Semaphorin–plexin signaling plays a major role in the tumor microenvironment (TME). In particular, Semaphorin 4D (SEMA4D) has been shown to promote tumor growth and metastasis; however, the role of its high-affinity receptor Plexin-B1 (PLXNB1), which is expressed in the TME, is poorly understood. In this study, we directly targeted PLXNB1 in the TME of triple-negative murine breast carcinoma to elucidate its relevance in cancer progression. We found that primary tumor growth and metastatic dissemination were strongly reduced in PLXNB1-deficient mice, which showed longer survival. PLXNB1 loss in the TME induced a switch in the polarization of tumor-associated macrophages (TAM) toward a pro-inflammatory M1 phenotype and enhanced the infiltration of CD8+ T lymphocytes both in primary tumors and in distant metastases. Moreover, PLXNB1 deficiency promoted a shift in the Th1/Th2 balance of the T-cell population and an antitumor gene signature, with the upregulation of Icos, Perforin-1, Stat3, and Ccl5 in tumor-infiltrating lymphocytes (TILs). We thus tested the translational relevance of TME reprogramming driven by PLXNB1 inactivation for responsiveness to immunotherapy. Indeed, in the absence of PLXNB1, the efficacy of anti-PD-1 blockade was strongly enhanced, efficiently reducing tumor growth and distant metastasis. Consistent with this, pharmacological PLXNB1 blockade by systemic treatment with a specific inhibitor significantly hampered breast cancer growth and enhanced the antitumor activity of the anti-PD-1 treatment in a preclinical model. Altogether, these data indicate that PLXNB1 signaling controls the antitumor immune response in the TME and highlight this receptor as a promising immune therapeutic target for metastatic breast cancers.